Long-Term Efficacy of Insulin Glargine After Switching from NPH Insulin as Intensive Replacement of Basal Insulin in Japanese Diabetes Mellitus. Comparison of Efficacy between Type 1 and Type 2 diabetes (JUN-LAN Study 1.2)

  • KANAZAWA Yoshie
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine
  • IGARASHI Yasuhiro
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine
  • KOMIYA Koji
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine
  • SAKURAI Yuko
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine
  • SHIMIZU Tomoaki
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine
  • FUJITANI Yoshio
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine Center for Therapeutic Innovations in Diabetes, Juntendo University, School of Medicine
  • TANAKA Yasushi
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine Metabolism and Endocrinology, Department of Medicine, St. Marianna University School of Medicine
  • WATADA Hirotaka
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine
  • KAWAMORI Ryuzo
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine Center for Therapeutic Innovations in Diabetes, Juntendo University, School of Medicine
  • HIROSE Takahisa
    Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine Center for Therapeutic Innovations in Diabetes, Juntendo University, School of Medicine

この論文をさがす

抄録

To assess and compare the efficacy and safety of insulin glargine as intensive replacement of basal insulin in Japanese patients with type 1 (n = 72) and type 2 (n = 46) diabetes, we switched their intensive insulin regimen from NPH plus regular or rapid-acting insulin to glargine plus bolus insulin, which included regular and rapid-acting insulin, and recorded changes in glycemic control and frequency of hypoglycemia for 18 months. The dose titration of basal and bolus insulin was based on home self-monitored blood glucose measurements and monthly HbA1C. Mean HbA1C level was improved significantly at 3 months after switching to glargine plus bolus insulin regimen and these effects continued for 18 months in both type 1 and type 2 diabetes patients (HbA1C level: type 1: baseline 8.9 ± 2.6%, 18 months 7.8 ± 1.5% (p<0.05), type 2: baseline 8.2 ± 2.6%, 18 months 7.7 ± 1.5%. Body weight was slightly but significantly increased at 18 months only in type 2 diabetes. Total daily bolus insulin doses were not changed but basal insulin could be increased significantly after switching regimens in both types diabetes compared with baseline. The frequency of mild to moderate hypoglycemia (self-assisted episodes, blood glucose <70 mg/dl) was marginally lower with glargine but not significantly. Self-monitored fasting blood glucose level was significantly improved after switching in type 2 diabetes. Patients with the worst HbA1C level at baseline exhibited more than 10% improvement in HbA1C level after switching both type 1 and type 2 diabetes. The HbA1C levels of the effectively treated patients were comparable to those of ineffectively treated ones at 6 months and the same improvement was seen at 18 months. Our results suggested that insulin glargine is more effective than NPH insulin as intensive replacement of basal insulin, particularly in those Japanese patients with difficult glycemic control with NPH insulin, equally in both type 1 and type 2 diabetes.<br>

収録刊行物

  • Endocrine Journal

    Endocrine Journal 54 (6), 975-983, 2007

    一般社団法人 日本内分泌学会

被引用文献 (2)*注記

もっと見る

参考文献 (42)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ